The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Thu, 22nd Oct 2020 11:06

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 250 - LOSERS

----------

Shaftesbury, down 13%, and Capital & Counties, down 11%. Shaftesbury said it intends to raise GBP307 million via the issue of new shares to ensure financial flexibility to navigate the "unprecedented" challenges created by the Covid-19 pandemic. Current market capitalisation is GBP1.33 billion. Capital & Counties Properties said it will participate in the Shaftesbury fundraise by providing GBP65 million.

----------

Moneysupermarket, down 5.7%, the price comparison website firm said revenue dropped across all of its businesses in the third quarter, with the company blaming the "disruption" caused by the pandemic. In the three months to September 30, Moneysupermarket's total revenue dropped 16% year on year to GBP85.1 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Premier African Minerals up 19%. The southern Africa-focused miner said it has settled all amounts it owes to directors, employees and other creditors, amounting to GBP600,057 of shares. Along with the GBP1.1 million placing, completed on Wednesday, the company is now debt free.

----------

OPG Power Ventures, up 16%. The Indian power plant operator said revenue in the year ended March 31 rose 9.5% to GBP154.0 million from GBP140.6 million. Pretax profit slipped 14% to GBP14.5 million from GBP16.9 million.

----------

4D Pharma up 16% after it proposed a merger with special-purpose acquisition company Longevity Acquisition Corp. Longevity shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each - an 18% premium to its GBP0.932 closing price on Wednesday - GBP144.5 million altogether. 4D's current market capitalisation is GBP141.1 million. The enlarged company will also launch an American depositary receipts programme, eyeing a Nasdaq listing.

----------

Pendragon up 12%, the motor retailer said it delivered a "very strong" third quarter, with total revenue down 14% annually, but up 1.2% like-for-like. Underlying pretax profit surged to GBP27.3 million from GBP3.0 million a year earlier. Opts not to reinstate annual guidance, however.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Kibo Energy, down 12% after the Africa-focused energy firm posted a narrowed loss in the six months to June 30. Its pretax loss slimmed to GBP1.3 million from GBP1.8 million, though like last year, it generated no revenue. Noted that Covid-19 has caused delays to its project development targets.

----------

Thalassa Holdings, dropped 12% after a regulatory filing showed investor Lombard Odier Asset Management Ltd trimmed its stake in the British Virgin Islands-based investment holding company to 1.4% from 14% during a transaction on Wednesday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2022 11:07

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.

Read more
1 Apr 2022 09:56

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
1 Apr 2022 08:11

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded

4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30.3 million the year before.

Read more
23 Mar 2022 11:21

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
23 Mar 2022 11:16

4d Pharma shares jump on positive results from cancer treatment study

(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytruda for the treatment of renal cell carcinoma showed positive results.

Read more
9 Mar 2022 19:26

IN BRIEF: 4D Pharma registers for potential ADS offering in US

4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following which the company may offer up to USD150.0 million of shares in the form of American Depositary Shares, with each ADS reflecting eight ordinary shares.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2022 09:55

4d Pharma gets FDA clearance for potential Parkinson's treatments

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has cleared investigational new drug applications for 'MRx0005' and 'MRx0029', for the treatment of Parkinson's disease.

Read more
27 Jan 2022 13:20

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

Read more
4 Jan 2022 10:32

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

Read more
13 Dec 2021 10:55

4D Pharma announces positive results in asthma treatment trials

4D Pharma announces positive results in asthma treatment trials

Read more
30 Sep 2021 11:05

4D Pharma pretax loss grows in first half after Spac merger costs

4D Pharma pretax loss grows in first half after Spac merger costs

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
26 Jul 2021 16:23

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

Read more
4 Jun 2021 10:32

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.